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ABSTRACT
Objective: To determine whether sickle cell carriers
(‘sickle cell trait’) have an increased risk of venous
thromboembolism (VTE).
Design: Cohort study with nested case–control
analysis.
Setting: General population with data from 609 UK
general practices in the Clinical Practice Research
Datalink (CPRD).
Participants: All individuals registered with a CPRD
general practice between 1998 and 2013, with a
medical record of screening for sickle cell between 18
and 75 years of age.
Main outcomes measures: Incidence of VTE per
10 000 person-years (PY) among sickle cell
carriers and non-carriers; and adjusted OR for
VTE among sickle cell carriers compared with non-
carriers.
Results: We included 30 424 individuals screened for
sickle cell, with a follow-up time of 179 503 PY,
identifying 55 VTEs in 6758 sickle cell carriers and 125
VTEs in 23 666 non-carriers. VTE incidence among
sickle cell carriers (14.9/10 000 PY; 95% CI 11.4 to
19.4) was significantly higher than non-carriers (8.8/
10 000 PY; 95% CI 7.4 to 10.4). Restricting analysis to
confirmed non-carriers was non-significant, but
performed on a small sample. In the case–control
analysis (180 cases matched to 1775 controls by age
and gender), sickle cell carriers remained at increased
risk of VTE after adjusting for body mass index,
pregnancy, smoking status and ethnicity (OR 1.78,
95% CI 1.18 to 2.69, p=0.006), with the greatest risk
for pulmonary embolism (PE) (OR 2.27, 95% CI 1.17
to 4.39, p=0.011).
Conclusions: Although absolute numbers are small,
in a general population screened for sickle cell,
carriers have a higher incidence and risk of VTE,
particularly PE, than non-carriers. Clinicians should
be aware of this elevated risk in the clinical care of
sickle cell carriers, or when discussing carrier
screening, and explicitly attend to modifiable risk
factors for VTE in these individuals. More complete
primary care coding of carrier status could improve
analysis.
INTRODUCTION
Sickle cell disease (SCD) is a group of reces-
sively inherited haemoglobin disorders
causing anaemia, vascular occlusion and
increased venous thromboembolism (VTE).1
People with sickle cell trait (SCT) are car-
riers who inherit one sickle haemoglobin
gene and one normal haemoglobin gene.
There are an estimated 300 million indivi-
duals worldwide with SCT, with the highest
frequency of carriage in people of African or
Middle Eastern origin, with increased rates
among those of Mediterranean descent.2 3
There are at least 240 000 people with SCT
in England, and an estimated 4 million indi-
viduals in the USA.4 5
SCT has important implications for genetic
reproductive risk to offspring but is otherwise
considered relatively harmless to the indivi-
dual’s health, manifesting no complications
of SCD itself other than, rarely, in situations
of severe dehydration or hypoxia such as at
high altitude.6 However, concerns about
other morbidity and mortality associated with
being a sickle cell carrier have long been
debated. These include reports of sudden
exercise-related death in military recruits and
Strengths and limitations of this study
▪ The study used a large primary care database
representative of the UK population.
▪ The database was interrogated over a 25-year
time period, and included a large number of indi-
viduals screened for sickle cell.
▪ The findings from the main cohort study were
consolidated by a nested case–control study.
▪ In the primary care database, there is limited
recording of non-carrier status and ethnicity.
▪ No external source of data was available to verify
carrier status and outcomes.
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college sportsmen.7–10 The US National Collegiate
Athletic Association’s mandatory SCT screening pro-
gramme for student athletes has provoked considerable
controversy about whether this will improve outcomes,
while also leading to discrimination and confusion.4 11 12
Recently, SCT has also been shown to be associated with
chronic kidney disease.13
Arguably of greater relevance to all people who are
sickle cell carriers and routine clinical practice are
reports of increased risk of VTE.2 14–16 However, rather
than draw from the general population, these studies
have involved selected samples already at higher risk of
thromboembolism, such as hospitalised patients,15 17 18
individuals in the peripartum period19 or have focused
solely on African-Americans.16 20 For example, in a case–
control study of hospitalised African-Americans, the like-
lihood of VTE was approximately twice as high among
those with SCT compared with non-carriers.15 However,
more robust evidence on potential morbidity related to
SCT in the wider general population is lacking.
In the UK, as far back as 1993, policymakers have
recommended that primary care should screen patients
opportunistically for SCT to identify potential genetic
reproductive risk, for example, when they registered
with a practice.21 The identiﬁcation of SCT has greater
signiﬁcance now that several countries are establishing
national population screening programmes for sickle
cell. For example, since 2003, women in the UK have
been routinely offered screening for sickle cell carrier
status in pregnancy to better inform reproductive risk
assessment, and all newborn babies are offered screen-
ing for SCD (which also identiﬁes carriers).22 Similar
newborn screening has been offered in New York State
since 1975, with universal newborn sickle cell screening
throughout the USA since 2006.23 These screening pro-
grammes are increasing the number of people identiﬁed
with SCT in general populations and so achieving a
better understanding of possible implications for their
health is needed. The aim of this study therefore was to
investigate potential associations between SCT and risk
of VTE in the general population.
METHODS
Study design and setting
We conducted an open cohort study with nested case–
control analysis of patient medical data from the UK’s
Clinical Practice Research Datalink (CPRD). In the UK,
the general practitioner holds the lifelong medical
record of all patients registered with their practice and
98% of the UK population is registered with a general
practitioner.24 The CPRD contains an anonymised copy
of these medical records for more than 12 million
patients from over 600 general practices across the UK,
comprising one of the largest sources of continuous
medical and prescribing data in the UK.25 Patient data
regarding primary, secondary and tertiary healthcare
usage are documented in an electronic health record
using the Read code classiﬁcation system, based on the
International Classiﬁcation of Diseases V.10. It includes
prescription data, medical diagnoses, symptoms, test
results, treatments and records of secondary care attend-
ance. Patient records in CPRD are representative of the
UK population26 27 and of good quality for epidemio-
logical research, including for VTE events.28–30
Study participants
Study participants were registered with 609 CPRD prac-
tices between February 1988 and May 2013 and had
been screened for sickle cell between age 18 and
75 years. Participants entered the study at the latest of 1
January of the year of their 18 birthday, their date of
practice registration or the date that the practice
attained the recognised data quality standard for CPRD.
Participants were followed up until the earliest of the 1
January of the year of their 75 birthday, date of death,
date of transfer out from the practice, the last collection
date of data from the practice or the occurrence date of
the ﬁrst VTE event.
Patients were classiﬁed as having SCT if they had a
diagnostic code for SCT or recorded laboratory test
result conﬁrming carrier status (with or without a
medical code entry indicating screening for sickle cell).
For the main analysis, patients were classiﬁed as not
having SCT (non-carriers) if they had a medical code
indicating sickle cell screening at any age and had no
result recorded in their medical records, or had a
medical code or test results indicating non-carrier status.
A sensitivity analysis was undertaken that only included
patients with conﬁrmed non-carrier status, thus exclud-
ing individuals who did not have a diagnostic code or
recorded laboratory test result for non-carrier status.
Patients were considered to have had a VTE if they had
a validated diagnostic medical code for VTE in their
record during the observational period (February 1988–
May 2013).29 We included only the ﬁrst occurrence of
VTE between the ages of 18 and 75 years while regis-
tered in a CPRD practice. We excluded patients with
documented VTE prior to cohort entry or with a history
of anticoagulant therapy more than 6 weeks prior to the
date of VTE as this could indicate a previous VTE.
Individuals with a medical diagnosis of SCD were
excluded from the study. Code lists for VTE, sickle cell
screening, carrier and non-carrier status are in online
supplementary material.
Main outcome measures
Our main outcome for the cohort analysis was the inci-
dence rate of VTE per 10 000 person-years (PY) among
carriers and non-carriers. In the nested case–control
analysis, our main outcome was the adjusted OR for
VTE among carriers compared with non-carriers.
Cohort analysis
The cohort was described by frequencies and percen-
tages of carriers and non-carriers in groups deﬁned by
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gender, ethnicity and socioeconomic status. The
Townsend Deprivation Index of material deprivation was
used to assess the socioeconomic proﬁle of the cohort.31
Incidence rates of ﬁrst VTE were calculated by divid-
ing the number of new cases by PY of follow-up.
Incidence rates for subcategories of VTE were also calcu-
lated, including deep venous thrombosis (DVT) and pul-
monary embolism (PE) and other, rarer VTE, such as
retinal vein thrombosis and cerebral venous thrombosis.
We used the Mantel-Haenszel method to compare inci-
dence rates between carrier and non-carrier groups.
Data management and statistical analyses were per-
formed using Stata V.13.
Nested case–control study
We undertook a nested case–control study to investigate
the association between VTE outcome and carrier status,
taking into account potential confounding factors. The
case–control study was based on the underlying cohort
where matched controls were randomly selected from all
remaining participants at risk, including potential future
cases.32 Estimates obtained from nested case–control
studies and from underlying cohorts have been shown to
be similar.33 This design also allowed us to use data for
confounding factors ascertained at the closest time
before the VTE date, thus simplifying the analysis of
time-dependent exposures.
The controls were matched by year of birth and
gender and allocated an index date, which was the VTE
diagnosis date for their matched case. Controls with anti-
coagulant therapy at any time before the index date
were excluded from the analysis.
Case–control analysis
We used conditional logistic regression to estimate
unadjusted and adjusted ORs and 95% CIs for VTE in
carriers compared with non-carriers. For the multivari-
able analysis, we matched for age and sex, and adjusted
for a priori confounders: ethnicity, smoking status, body
mass index (BMI) and pregnancy.
Validation of VTE events recorded in primary care has
demonstrated that the vast majority are supported by
relevant hospital investigations or death certiﬁcation.29
However, to account for any potential misclassiﬁcation
of cases and controls by relying on diagnostic recording
of VTE in primary care records, we undertook a sub-
group analysis using a more stringent deﬁnition of VTE
diagnosis, in which VTE occurrence was supported by
one of the following: a documented prescription for war-
farin or low-molecular weight heparin within 3 months
of the date of diagnosis; or evidence of attendance at a
clinic for treatment with anticoagulants within 3 months
of diagnosis; or death within 1 month of diagnosis.34 35
We included ethnicity, pregnancy, BMI and smoking
status as covariates. We selected these because within the
UK, minority ethnic groups are more likely to be offered
sickle cell testing, risk of ﬁrst VTE in pregnant women is
at least sixfold,36 37 obesity is associated with a 2–3 times
increased risk of VTE38 39 and smoking with a 1.5 times
increased risk.40 41 BMI and smoking are routinely
recorded in UK primary care electronic health
records.42 43 Smoking status and BMI data were extracted
using the closest record prior to the index date.
Smoking status was categorised into: current smokers,
ex-smokers and non-smokers. BMI was deﬁned as weight
(in kilograms) divided by the square of height (in
metres), and categorised into <25, 25–29 and ≥30.
Ethnicity was extracted from primary care records or,
where not available, from linked hospital electronic
health records (HES) and categorised as: White; Asian
(comprising ethnic groups from the Indian subcontinent
and China); Black (indicative of African ancestry); Other
(including mixed ethnicity). Ethnicity was self-reported
by patients attending General Practice or Hospital, and
was grouped by investigators. Pregnancy included the
ﬁrst 3 months after delivery and was deﬁned using preg-
nancy codes and the estimated conception date of deliv-
ery minus 280 days or delivery date minus gestational age
if recorded.44 Since pregnancy and the postpartum
period is associated with increased risk of VTE,45 we
undertook a sensitivity analysis removing pregnant
women from the analysis. Subgroup analysis of VTE and
SCT in Black people was also undertaken to allow direct
comparison with the previous literature.15 16 18
To retain the statistical power and obtain unbiased
results, all observations were included in the analysis.
Chained equations were used to impute missing values
for the covariates.46 Ten imputed sets were generated
and the imputation model: matching variables (age and
gender); exposure (carrier, non-carrier); outcome (case
or control); covariates (pregnancy, logarithm of BMI,
smoking status and ethnicity); UK region (because the
ethnicity proﬁle differs by regions); index year.47 The
results from the imputed sets were combined using
Rubin’s rules.46 To ensure the assumption that the data
were missing at random, we ran a sensitivity analysis on
patients with complete data.
Patient involvement
The study was a retrospective, quantitative, observational
study using information routinely collected by general
practices and a similar linked source of census data. The
design and the development of outcome measures were
necessarily technical, based in part on earlier publica-
tions and medical expertise within the team, but primar-
ily on examination of available data in order to
maximise inclusiveness and length of study period. As
such, patients were not involved in any of these aspects.
However, as well as dissemination through this publica-
tion, we are working with sickle cell patient groups to
produce lay summaries describing the research and its
results. With respect to the use of the CPRD database,
the CPRD Group has ethical approval from a National
Research Ethics Service Committee (NRES) for all
research not including patient involvement and using
anonymised data.
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RESULTS
Cohort analysis
During the study period, 45 746 individuals had a record
of sickle cell screening in their medical records. After
exclusions (ﬁgure 1), the cohort analysis included
30 424 individuals; 6758 individuals with SCT (carriers)
and 23 666 without SCT (non-carriers). Overall, 82.5%
of individuals were women, with a higher proportion in
the non-carrier group than the carrier group (86.9% vs
67.3%, respectively) (table 1). Ethnicity was recorded for
more than 80% of the study population and of those
with recorded ethnicity, 53.4% of the carrier group and
15.8% of the non-carrier group were Black.
One hundred and eighty VTEs were identiﬁed within
a total follow-up time of 179 503 PY. The median
follow-up time was 3.71 years in the carrier group and
4.68 years in the non-carrier group. The incidence of
VTE was 14.9 (95% CI 11.4 to 19.4) per 10 000 PY in
carriers, and 8.8 (95% CI 7.4 to 10.4) per 10 000 PY in
non-carriers (table 2). Considering VTE subgroups, the
difference in incidence rates was greatest for PEs and
not signiﬁcant for DVT. Sensitivity analysis with con-
ﬁrmed non-carriers identiﬁed low event rates in this
subgroup, leading to wide CIs but showed a consistent
pattern of results to the main analysis (see online
supplementary table S1).
Nested case–control analysis
A total of 180 cases were matched to 1775 controls by
gender and year of birth. Cases and controls had similar
proﬁles with the majority of participants being women
(table 3). The proportion of obese patients was higher
among cases (31.1% compared with 20.6% of controls,
p<0.001), and women were more likely to be pregnant
in cases (29.4% of female cases) than in controls (16.4%
of female controls).
After adjusting for a priori confounders (see online
supplementary table S2), carriers were 1.78 times more
likely to have a VTE than non-carriers (OR 1.78, 95%
CI 1.18 to 2.69) and the odds of PE in carriers
increased even further (OR 2.27, 95% CI 1.17 to 4.39)
(table 4). The odds of DVT were increased in carriers,
although this was not signiﬁcant (OR 1.43, 95% CI 0.79
to 2.59).
When we restricted the case deﬁnition of VTE to
include cases with a diagnostic medical code for VTE,
supported by a record of anticoagulant therapy, clinic
attendance or death, there was a more than twofold
increased odds of VTE in carriers (OR 2.71, 95% CI
1.52 to 4.83). After removal of pregnant women from
the cohort, the odds of VTE in carriers compared
with non-carriers remained consistent at 1.80 (95% CI
1.15 to 2.83).
Figure 1 Flow chart of patients
in the cohort study. CPRD,
Clinical Practice Research
Datalink; VTE, venous
thromboembolism.
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There were 27 VTE events in the subgroup of 7343
Black patients. The incidence rate of VTE was 12.9 per
10 000 PY; 15.5 per 10 000 PY in carriers and 10.6 per
10 000 PY in non-carriers (incidence rate ratio 1.45, 95%
CI 0.82 to 2.59, p=0.2). In the case–control analysis, 47
cases were matched by age and gender to 418 controls.
After adjusting for covariates, the VTE risk associated
with SCT carrier in this subgroup was in line with the
main analysis (OR 1.73, 95% CI 0.91 to 3.32, p=0.096).
DISCUSSION
In a large general population cohort screened for sickle
cell over a 25-year period, we have found SCT was asso-
ciated with a signiﬁcantly increased likelihood of VTE,
in particular, PE.
The ﬁndings from the cohort study were consolidated
by a nested case–control study.48 Analysis of VTE based
solely on medical code recording does include the
potential for false-positive diagnoses. However, 84% of
VTEs reported in primary care have been validated
through hospital records or death records.29 Our study
ﬁndings were consistent when a more stringent
deﬁnition of VTE (combining evidence from medical
diagnoses, drug therapies and/or clinic attendance)
was used.
Strengths and limitations of the study
A major strength of this study is the investigation and
conﬁrmation of a signiﬁcant association between SCT
and VTE in a very much larger, more socially and ethnic-
ally diverse, general population than previous studies.
The CPRD contain data from patients that are consid-
ered representative of the general UK population.49 Our
cohort analysis included more than 30 000 individuals
screened for sickle cell, with almost 7000 carriers and
over 23 000 non-carriers, with an incidence of VTE
observed over nearly 180 000 years of person time. We
also note the VTE incidence in non-carriers is similar to
that reported in the UK general population.48
We recognise that only people who had screening
and/or testing documented in their medical record
Table 1 Characteristics of the study population and numbers and proportions of carriers and non-carriers for each category
Demographic characteristics Whole cohort Carriers Non-carriers
Total number of patients 30 424 6758 23 666
Age at study entry
Median (IQ range) 28 (22, 36) 32 (25, 41) 28 (22, 34)
Age at SCD test
Median (IQ range) 29 (23, 36) 28 (19, 36) 30 (24, 35)
Gender
Male (%) 5322 (17.5) 2213 (32.7) 3109 (13.1)
Female (%) 25 102 (82.5) 4545 (67.3) 20 557 (86.9)
Ethnicity
White (%) 8678 (28.5) 484 (7.2) 8194 (34.6)
Black (%) 7343 (24.1) 3608 (53.4) 3735 (15.8)
Asian (%) 3408 (11.2) 228 (3.4) 3180 (13.4)
Other (%) 5377 (17.7) 662 (9.8) 4715 (19.9)
Not recorded (%) 5618 (18.5) 1776 (26.3) 3842 (16.2)
Socioeconomic status
Quintile 1 (least deprived) 1784 (8.3) 325 (4.8) 1459 (6.2)
Quintile 2 1998 (9.3) 386 (5.7) 1612 (6.8)
Quintile 3 2417 (11.3) 602 (8.9) 1815 (7.7)
Quintile 4 4125 (19.2) 1179 (17.4) 2946 (12.4)
Quintile 5 (most deprived) 6876 (32.0) 2254 (33.4) 4622 (19.5)
Missing 4278 (19.9) 2012 (29.8) 11 212 (47.4)
Table 2 Incidence rates per 10 000 person-years (PY) for venous thromboembolism (VTE), deep vein thrombosis (DVT),
pulmonary embolism (PE) and other VTEs by carrier status
Carrier Non-carriers
Incidence rate
ratio (95% CI) p Value
Number of
events
Incidence rate per
10 000 PY (95% CI)
Number of
events
Incidence rate per
10 000 PY (95% CI)
VTE 55 14.9 (11.4 to 19.4) 125 8.77 (7.35 to 10.4) 1.70 (1.24 to 2.33) 0.001
DVT only 24 6.53 (4.37 to 9.74) 83 5.83 (4.70 to 7.23) 1.12 (0.71 to 1.76) 0.2
PE only 26 7.07 (4.81 to 10.4) 36 2.53 (1.83 to 3.51) 2.79 (1.69 to 4.62) <0.001
Other VTE 5 1.36 (0.57 to 3.28) 6 0.42 (0.19 to 0.94) 3.23 (0.99 to 10.6) 0.041
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were included, potentially missing others in the popula-
tion who had been screened for sickle cell. However, the
introduction of universal sickle cell and thalassaemia
antenatal carrier screening in the UK in 2003 will have
improved recording, with universal screening across the
entire antenatal population in areas with higher preva-
lence of SCD (more than 1.5 per 10 000 births).50 This
is reﬂected in the study population, which, as expected,
was mostly screened around reproductive age with pro-
portionally more women, while still representative of the
Table 3 Characteristics of cases and controls: frequencies and proportions
Cases frequency (%)
n=180
Controls frequency (%)
n=1775 Adjusted ORs (95% CIs)*
Sex
Male 42 (23.3) 409 (23.0)
Female 138 (76.7) 1366 (77.0)
Age at first VTE/index date
18–34 83 (46.1) 828 (46.6)
35–54 62 (34.4) 615 (34.6)
55–74 35 (19.4) 332 (18.7)
Ethnicity
White 59 (32.8) 518 (29.2) Reference
Black 47 (26.1) 431 (24.3) 0.74 (0.47 to 1.17)
Asian 14 (7.8) 176 (9.9) 0.82 (0.41 to 1.63)
Other 32 (17.8) 299 (16.8) 0.89 (0.56 to 1.40)
Not recorded 28 (15.6) 351 (19.8)
Smoking status
Non-smokers 104 (57.8) 1058 (59.6) Reference
Ex-smokers 34 (18.9) 275 (15.5) 1.18 (0.76 to 1.85)
Smokers 31 (17.2) 331 (18.6) 1.05 (0.67 to 1.63)
Not recorded 11 (6.1) 111 (6.3)
BMI
BMI mean (SD) 28.7 (6.0) 26.5 (5.5)
<25 kg/m2 44 (24.4) 694 (39.1) Reference
25–29 kg/m2 59 (32.8) 479 (27.0) 2.05 (1.30 to 3.23)
30+ kg/m2 56 (31.1) 365 (20.6) 2.69 (1.67 to 4.33)
Not recorded 21 (11.7) 237 (13.4)
Pregnant
No 127 (70.6) 1484 (83.6) Reference
Yes 53 (29.4) 291 (16.4) 1.45 (1.25 to 1.69)
*ORs refer to multivariate analysis on imputed data investigating the effect of the covariates to VTE risk. Cases and controls were matched by
age and sex, so ORs were not calculated for these variables.
Table 4 Unadjusted and adjusted ORs of thrombotic events in patients with sickle cell trait (SCT), compared with patients
without SCT, main and subgroup analyses
Cases Controls OR* Adjusted OR† p Value
Main analysis
VTE
Non-carrier 125 1369 1.00 1.00 –
Carrier 55 406 1.55 (1.09 to 2.21) 1.78 (1.18 to 2.69) 0.006
DVT only
Non-carrier 83 841 1.00 1.00 –
Carrier 24 207 1.18 (0.71 to 1.95) 1.43 (0.79 to 2.59) 0.2
PE
Non-carrier 36 449 1.00 1.00 –
Carrier 26 170 2.09 (1.17 to 3.72) 2.27 (1.17 to 4.39) 0.011
Subgroup analysis
VTE definition included anticoagulant therapy, clinic attendance or death
Non-carrier 60 725 1.00 1.00 –
Carrier 36 223 2.20 (1.36 to 3.57) 2.71 (1.52 to 4.83) 0.001
*Matched by age and sex.
†Adjusted for age, sex, pregnancy, BMI, smoking status and ethnicity.
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broad ethnic and social diversity of the UK general
population.
The majority of people had a record of screening but
no result recorded and these participants were assumed
to be non-carriers in our main analysis, as this would
be consistent with clinical practice. However, some with
no results recorded may have been carriers. The pres-
ence of carriers in the unconﬁrmed non-carriers (no
test) group would reduce the effect size of the main
analysis. Further, GPs are more likely to document
carrier state than non-carrier state introducing recall
bias. Restricting participants to only those with docu-
mented carrier and non-carrier status resulted in inci-
dence rates and incidence rate ratios that were
consistent with the main analysis, although underpow-
ered due to the restricted number of events. We also
only used patient data that were considered to be of
sufﬁcient quality (in terms of completeness and accur-
acy) as determined by CPRD (ie, identiﬁed as ‘up to
standard’ within the database). However, we were only
able to take account of confounding factors that are
recorded in the electronic health record. Similarly,
while free-text information on diagnostic imaging is
inconsistent and not accessible to researchers in elec-
tronic primary care records, the prevalence of PE in
the carrier group could potentially reﬂect ascertain-
ment bias, if, for example, clinicians had a lower index
of suspicion for lung problems in carriers, with more
frequent diagnostic imaging.
Comparison with recent studies
Our ﬁndings are consistent with previous North
American studies in demonstrating a relationship
between SCT and VTE, but conﬁrm this not only in a
much larger general population sample but also across
socioeconomic groups and ethnicities. Based on our
subgroup and adjusted analyses, the difference in VTE
incidence rates could not be attributed to difference in
the ethnicity of carriers and non-carriers in our study.
Our results are also consistent with previous observa-
tional studies with smaller or more selected popula-
tions.15 16 18 20 Similar to our ﬁndings, Austin et al15
reported a higher risk of PE among hospitalised black
Americans with SCT, with no increased risk of DVT in
carriers compared with non-carriers. An earlier retro-
spective cohort study of hospitalised black men found
PE occurring in 2.2% of carriers compared with 1.5% in
non-carriers, though diagnosis of PE was based solely on
clinical criteria.18 Recent cohort studies, again of
African-Americans only, have reported no increased
overall risk of VTE but up to a twofold increased risk of
PE.16 20 The possible causes for this increased risk of
VTE remain unclear but may, in part, be related to
increased coagulation activity found in SCT.51 Ideally,
future research should explore the relationship between
SCT and VTE in a prospective birth cohort systematically
offered neonatal screening for sickle cell with carrier
and non-carrier state accurately documented. If primary
care records are to be used in future research, the
coding of non-carrier status needs to be improved, for
example, through direct coding of carrier status when
results are transferred electronically to primary care
records from pathology laboratories.
Implications for clinical practice
Currently, individuals identiﬁed with SCT are advised
that their carrier state is relatively harmless to their
health, with caution required only in unusual conditions
of severe dehydration or hypoxia such as extreme exer-
tion, anaesthesia or high altitude. Although the absolute
numbers of VTE events were small, our results indicate
that clinicians should make patients with SCT aware of
their increased risk of VTE and stress the particular
importance of attending to modiﬁable risk factors, such
as obesity and smoking. Compared with other conven-
tional risk factors, the risk of VTEs with carrier status is
similar to pregnancy, obesity and prolonged bed rest.36
The evidence may now be sufﬁciently robust to consider
SCT a signiﬁcant non-modiﬁable risk factor in evaluating
patients’ VTE risk. In the clinical setting, this could
facilitate modiﬁcation of other coexistent risk factors of
VTE, such as obesity and immobility.
In relation to sickle cell screening, identiﬁcation of
carrier status is perceived as useful to inform individuals
about potential reproductive genetic risk—antenatally
and among parents of newborns.52 53 The current
ﬁnding of increased risk of VTE in sickle cell carriers
adds a further dimension to the appropriate provision of
information to patients in such screening contexts.
Given the experience of African-American communities
in the recent past, caution is needed to avoid stigmatisa-
tion and community anxiety11 54 55 in advancing appro-
priate care of people with SCT. Previous researchers
have observed the Black community, at genetic risk of
sickle cell, are also disadvantaged in society. A situation
exacerbated by racism.56 Such issues also deserve further
consideration. However, we also note our ﬁndings are
drawn from a large, socially and ethnically diverse
general population with SCT. Thus, this study’s implica-
tions for clinical practice are not conﬁned to a particu-
lar ethnic community, but rather apply to all.
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